Contineum Therapeutics, Inc. Class A Common Stock

CTNM · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$42$23-$24-$29
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$7$2$2$2
Change in WC$5-$1-$1$0
Other Non-Cash-$3-$5$3$1
Operating Cash Flow-$33$19-$20-$26
Investing Activities
PP&E Inv.-$1-$0-$0-$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$226-$142-$65-$67
Inv. Sales/Matur.$157$77$87$2
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$70-$66$22-$65
Financing Activities
Debt Repay.$0-$4-$1$0
Stock Issued$108$0$0$0
Stock Repurch.$0-$0-$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$1$60$0$80
Financing Cash Flow$109$56-$1$80
Forex Effect$0$0$0$0
Net Chg. in Cash$6$10$1-$11
Supplemental Information
Beg. Cash$16$6$5$16
End Cash$22$16$6$5
Free Cash Flow-$33$19-$20-$26
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Financial Statements & Key Stats | AlphaPilot